{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:47Z","timestamp":1789609127640,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100025276","name":"Novo Nordisk USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtha.2024.09.040","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T12:32:26Z","timestamp":1731414746000},"page":"824-835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Acquired hemophilia A: a narrative review and management approach in the emicizumab era"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-336X","authenticated-orcid":false,"given":"Patrick","family":"Ellsworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheh-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ann","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice D.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.09.040_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tmrv.2022.07.001","article-title":"Advances in acquired hemophilia A","volume":"36","author":"Poston","year":"2022","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2024.09.040_bib3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1538-7836.2007.02433.x","article-title":"Treatment of acquired hemophilia A","volume":"5","author":"Collins","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ijlh.12210","article-title":"Acquired hemophilia: a case report and review of the literature","volume":"36","author":"Mulliez","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/asheducation-2006.1.432","article-title":"Acquired factor VIII inhibitors: pathophysiology and treatment","author":"Ma","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.09.040_bib6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.09.040_bib9","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.09.040_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/hae.13685","article-title":"Relapse pattern and long-term outcomes in subjects with acquired haemophilia A","volume":"25","author":"Mizrahi","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib11","first-page":"255","article-title":"Acquired hemophilia A: current guidance and experience from clinical practice","volume":"13","author":"Pishko","year":"2022","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2024.09.040_bib12","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s40265-018-1027-y","article-title":"Prevention and management of bleeding episodes in patients with acquired hemophilia A","volume":"78","author":"Kn\u00f6bl","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.09.040_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-206911","article-title":"Acquired haemophilia A: the importance of early recognition in cases of spontaneous bleeding in the elderly","volume":"2014","author":"Patel","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtha.2024.09.040_bib14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.09.040_bib16","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2018-99-116973","article-title":"Emicizumab for the treatment of acquired hemophilia A: lessons learned from 4 very different cases","volume":"132","author":"Knoebl","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12185-022-03467-w","article-title":"ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database","volume":"117","author":"Ogawa","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jth.15208","article-title":"Should emicizumab be used in patients with acquired hemophilia A?","volume":"19","author":"Tiede","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Supplement 2","key":"10.1016\/j.jtha.2024.09.040_bib20","first-page":"S38","article-title":"Natural history and real-world data in rare diseases: applications, limitations, and future perspectives","volume":"62","author":"Liu","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"Supplement 81","key":"10.1016\/j.jtha.2024.09.040_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.12689","article-title":"Acquired haemophilia: an overview for clinical practice","volume":"95","author":"Kessler","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1756-0500-3-161","article-title":"Consensus recommendations for the diagnosis and treatment of acquired hemophilia A","volume":"3","author":"Collins","year":"2010","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jtha.2024.09.040_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0301-2115(02)00027-1","article-title":"Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage","volume":"103","author":"Howland","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2024.09.040_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0049-3848(01)00385-1","article-title":"Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease","volume":"104","author":"Matsumoto","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.09.040_bib25","first-page":"2721","article-title":"Acquired haemophilia A: a 15-year single-centre experience of demography, clinical features and outcome","volume":"11","author":"Guerrero Camacho","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.09.040_bib26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2024.09.040_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/hae.14233","article-title":"Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: a systematic literature review","volume":"27","author":"Dewarrat","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ajh.20702","article-title":"Postpartum acquired factor VIII inhibitors","volume":"81","author":"Franchini","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12785","article-title":"Acquired hemophilia following COVID-19 vaccination: case report and review of literature","volume":"6","author":"Happaerts","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.15598","article-title":"Management of acquired haemophilia A in severe Covid-19: haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis","volume":"89","author":"Gelbenegger","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.09.040_bib31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.09.040_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2298\/SARH10S1064E","article-title":"Acquired haemophilia syndrome: pathophysiology and therapy","volume":"138","author":"Elezovi\u0107","year":"2010","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.jtha.2024.09.040_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib34","article-title":"Emicizumab for the treatment of acquired hemophilia A: consensus recommendations from the GTH-AHA Working Group","author":"Pfrepper","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.09.040_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0950-3536(96)80067-9","article-title":"Acquired inhibitors","volume":"9","author":"Cohen","year":"1996","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib36","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib37","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2516.2012.02789.x","article-title":"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A","volume":"18","author":"Kempton","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib38","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2516.1998.440558.x","article-title":"Factor VIII inhibitors in mild and moderate-severity haemophilia A","volume":"4","author":"Hay","year":"1998","journal-title":"Haemophilia"},{"issue":"Supplement 4","key":"10.1016\/j.jtha.2024.09.040_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2516.2012.02829.x","article-title":"How I treat inhibitors in haemophilia","volume":"18","author":"Makris","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/hae.12784","article-title":"Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile","volume":"22","author":"Lillicrap","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib43","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V60.5.1103.1103","article-title":"Inactivation of factor VIII coagulant activity by two different types of human antibodies","volume":"60","author":"Gawryl","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12185-021-03249-w","article-title":"Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan","volume":"115","author":"Takeyama","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/hematology.2023000462","article-title":"The role of emicizumab in acquired hemophilia A","volume":"2023","author":"Poston","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.09.040_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.09.040_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2516.2007.01474.x","article-title":"Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal","volume":"13","author":"Sumner","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hae.13033","article-title":"Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data","volume":"23","author":"Amano","year":"2017","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.09.040_bib49","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0268-960X(15)30004-7","article-title":"The use of recombinant activated factor VII in patients with acquired haemophilia","volume":"29","author":"Tiede","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.09.040_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2018.12.006","article-title":"Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: data from the FAIR registry","volume":"174","author":"Zanon","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.09.040_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/vox.12726","article-title":"aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model","volume":"114","author":"Kim","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.jtha.2024.09.040_bib52","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.thromres.2015.10.032","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) for the treatment and prevention of bleeding in patients with acquired haemophilia: a sequential study","volume":"136","author":"Zanon","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.09.040_bib53","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"Supplement 5","key":"10.1016\/j.jtha.2024.09.040_bib54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2516.2010.02294.x","article-title":"Clinical issues in inhibitors","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib55","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/hae.13426","article-title":"Laboratory monitoring issues in recombinant porcine FVIII replacement in acquired haemophilia A","volume":"24","author":"Vanguru","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib56","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/hae.12852","article-title":"US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry","volume":"22","author":"Ma","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib57","first-page":"365","article-title":"Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies","volume":"15","author":"Mannucci","year":"2017","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2024.09.040_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/17474086.2015.1040758","article-title":"Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A","volume":"8","author":"Gomperts","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib59","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.09.040_bib60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2002.00125.x","article-title":"Porcine factor VIII: current status and future developments","volume":"8","author":"Hay","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study","volume":"18","author":"T\u00fcrkantoz","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib62","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1111\/hae.13038","article-title":"Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy","volume":"22","author":"Martin","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib63","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1182\/bloodadvances.2020002977","article-title":"Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort","volume":"4","author":"Ellsworth","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.09.040_bib64","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00063-018-0444-8","article-title":"[Successful treatment of acquired hemophilia A with recombinant porcine factor VIII]","volume":"114","author":"Trautmann-Grill","year":"2019","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"10.1016\/j.jtha.2024.09.040_bib65","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5603\/GP.2019.0063","article-title":"Treatment guidelines for acquired hemophilia A","volume":"90","author":"Windyga","year":"2019","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.jtha.2024.09.040_bib66","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bjh.12463","article-title":"United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO","volume":"162","author":"W Collins","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib67","article-title":"Acquired hemophilia A: a single-center study of 165 patients","volume":"8","author":"Yu","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/hae.13752","article-title":"The factor VIII:C\/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: a retrospective cohort study","volume":"25","author":"Trossaert","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"The Netherlands. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib70","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib71","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ajh.25642","article-title":"Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders","volume":"94","author":"Malpica","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.09.040_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3324\/haematol.10553","article-title":"Rituximab for the treatment of acquired antibodies to factor VIII","volume":"92","author":"Sperr","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.09.040_bib74","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13708","article-title":"A\u00a0low-dose rituximab regimen for first-line treatment of acquired haemophilia A","volume":"108","author":"Hunt","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: a multicenter, open-label, randomized noninferiority trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients","volume":"237","author":"L\u00e9vesque","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.09.040_bib78","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.12659\/AJCR.916783","article-title":"Emicizumab use in treatment of acquired hemophilia A: a case report","volume":"20","author":"Al-Banaa","year":"2019","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jtha.2024.09.040_bib79","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.922326","article-title":"Utilization of emicizumab in acquired factor VIII deficiency","volume":"21","author":"Hess","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jtha.2024.09.040_bib80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/hae.14664","article-title":"Emicizumab for the treatment of acquired hemophilia A: retrospective review of a single-institution experience","volume":"29","author":"Chen","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib82","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1111\/hae.14335","article-title":"Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A","volume":"27","author":"Chen","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib83","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib84","first-page":"549","article-title":"Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding","volume":"21","author":"Pasca","year":"2023","journal-title":"Blood Transfus"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.09.040_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136488","article-title":"An investigational dosing algorithm of emicizumab for prophylaxis in acquired hemophilia A","volume":"136","author":"Shima","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib86","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A\u00a0prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.040_bib87","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3389\/fimmu.2020.01920","article-title":"Update on transplacental transfer of igg subclasses: impact of maternal and fetal factors","volume":"11","author":"Clements","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.09.040_bib88","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in\u00a0patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib89","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2022-162237","article-title":"Efficacy and safety of emicizumab prophylaxis in patients with acquired hemophilia a who were deemed ineligible for immunosuppressive therapy: additional data from the Ageha Study","volume":"140","author":"Nishikii","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.09.040_bib90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-139712","article-title":"In hemophilia \u0391 plasma treated with emicizumab, factor IX activation by factor VIIa drives thrombin generation","volume":"136","author":"Monroe","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.040_bib91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2024.03.023","article-title":"Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in\u00a0vitro","volume":"237","author":"Yada","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.09.040_bib92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/imj.14773","article-title":"Acquired haemophilia and haemostatic control with recombinant porcine factor VIII: case series","volume":"51","author":"Campbell","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtha.2024.09.040_bib93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13040","article-title":"Recombinant porcine sequence factor VIII (pFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients","volume":"23","author":"Tarantino","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1365-2516.2001.00488.x","article-title":"Acquired haemophilia: experiences with a standardized approach","volume":"7","author":"Gr\u00fcnewald","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.09.040_bib95","first-page":"328","article-title":"Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases","volume":"13","author":"Di Capua","year":"2015","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2024.09.040_bib96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1171-0522","article-title":"Critical bleeding in acquired hemophilia A: bypassing agents or recombinant porcine factor VIII?","volume":"41","author":"Tiede","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.09.040_bib97","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1016\/S2352-3026(23)00303-4","article-title":"Rapidly loading emicizumab without immunosuppression in acquired haemophilia","volume":"10","author":"Ragni","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.09.040_bib98","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"Schmitt","year":"2021","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:10:19Z","timestamp":1772327419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624006482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1538783624006482"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.09.040","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired hemophilia A: a narrative review and management approach in the emicizumab era","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}